Current Report Filing (8-k)
February 18 2020 - 5:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
February 18, 2020
Enzo Biochem, Inc.
(Exact Name of Registrant as Specified in Its
Charter)
New York
(State or Other Jurisdiction of Incorporation)
001-09974
|
13-2866202
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
527 Madison Avenue
|
|
New York, New York
|
10022
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(212) 583-0100
(Registrant’s Telephone Number, Including
Area Code)
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of Each Class
|
Trading Symbol
|
Name of Each Exchange on Which Registered
|
Common Stock, $.01 par value
|
ENZ
|
The New York Stock Exchange
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-1 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. o
On
February 18, 2020, Enzo Biochem, Inc., (“Enzo”)
issued an investor presentation that provides additional information to shareholders about proposal #1 on the agenda for
the 2019 Annual Meeting.
A
copy of the investor presentation is attached hereto as Exhibit
99.1 and is incorporated by reference herein.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
ENZO BIOCHEM, INC.
|
|
|
|
|
Date: February 18, 2020
|
By:
|
/s/ Barry W. Weiner
|
|
|
|
Barry W. Weiner
|
|
|
|
President
|
|
|
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Sep 2023 to Sep 2024